10 completed, 1 unknown. 6 Phase 2, 3 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Antigens, Surface: new trials by email Literature Review of Antigens, Surface trials Research Report on Antigens, Surface
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults ARCT-2138, Licensed Quadrivalent Vaccine for younger adults, Licensed Quadrivalent Vaccine for older adults - Influenza, Human | Phase 1 | Completed | Arcturus Therapeutics, Inc. | 139 | 2024-01-22 | 2025-10-03 |
| Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients Egg-derived standard dose trivalent influenza vaccine (surface antigen, inactivated) - ESRD, Influenza Vaccine | Phase 4 | Unknown | Mahidol University | 175 | 2021-03-01 | 2021-11-03 |
| Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated) - Influenza | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 665 | 2018-10-09 | 2022-04-04 |
| Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14) Inflexal V - Influenza | Phase 3 | Completed | Crucell Holland BV | 110 | 2013-07-01 | 2013-08-30 |
| Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains Inflexal V - Influenza | Phase 3 | Completed | Crucell Holland BV | 110 | 2012-07-01 | 2013-12-20 |
| Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011 - Seasonal Influenza | Phase 3 | Completed | Novartis Vaccines | 126 | 2010-07-01 | 2021-03-10 |
| Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Subjects Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009 - Influenza | Phase 2 | Completed | Novartis Vaccines | 143 | 2008-07-01 | 2012-01-05 |
| Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008 - Influenza | Phase 2 | Completed | Novartis Vaccines | 56 | 2007-06-01 | 2012-01-25 |
| Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008 - Influenza | Phase 2 | Completed | Novartis Vaccines | 125 | 2007-06-01 | 2016-12-01 |
| Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly Subjects Surface Antigen, Inactivated, (Adjuvanted with MF59C.1), form. 2006-07 - Influenza | Phase 2 | Completed | Novartis | 60 | 2006-06-01 | 2006-09-14 |
| Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older Surface Antigen, Inactivated, Influenza (form.2006-07) - Influenza | Phase 2 | Completed | Novartis | 100 | 2006-06-01 | 2006-09-14 |
Influenza, Human (11) · Virus Diseases (2) · Kidney Failure, Chronic (1)
Novartis Vaccines (4) · Crucell Holland BV (2) · Novartis (2) · Arcturus Therapeutics, Inc. (1) · Mahidol University (1) · Sanofi Pasteur, a Sanofi Company (1)
Italy (4) · Switzerland (2) · Australia (1) · Canada (1) · Germany (1) · Thailand (1) · United Kingdom (1) · United States (1)
Michael Seiberling, MD (1) · Milko Radicioni, MD (1)
2008 (1), 2018 (1)